Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer

Zhao, Wenjing; Li, Xiaoyan; Wang, Wenqing; Chen, Bing; Wang, Limin; Zhang, Ning; Wang, Zhe; Yang, Qifeng

doi:10.1155/2021/5529106

Cited by 14 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are studies indicating that the use of CA 15-3, a tumor marker used in the diagnosis and follow-up of breast cancer patients, along with CEA, CA 27.29, and radiological imaging, can be beneficial in monitoring metastatic lesions[ 65 ].…”

Section: Discussionmentioning

confidence: 99%

Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions

Dilek,

Arslan Kahraman,

Kahraman

2024

World J Gastrointest Surg

View full text Add to dashboard Cite

In this editorial review, we comment on the article published in the recent issue of the World Journal of Gastrointestinal Surgery . Carcinoembryonic antigen (CEA) is a fetal glycoprotein and can be secreted in very small amounts from healthy adults after birth. CEA is widely used not only for diagnostic tumor markers but also importantly for the management of some gastrointestinal tumors. The most common clinical use is surveillance for the monitoring of colorectal carcinoma. However, CEA can become elevated in several malign or benign characterized pathologies. Serum CEA level may vary depending on the location of the lesion, whether it metastasizes or not, and its histopathological characteristics. It has been determined that cases with high preoperative CEA have a more aggressive course and the risk of metastasis to the lymph tissue and liver increases. In this editorial review, we focused on evaluating the role of CEA in clinical practice with a holistic approach, including the diagnostic and prognostic significance of CEA in patients with focal liver lesions, the role of CEA in follow-up after definitive surgery, and also hepatic resection for metastasis, and the management of all patients with raised CEA.

show abstract

Section: Discussionmentioning

confidence: 99%

Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions

Dilek,

Arslan Kahraman,

Kahraman

2024

World J Gastrointest Surg

View full text Add to dashboard Cite

show abstract

“…The 85 subjects included in the aforementioned study included 18 patients with BC with distant metastasis; in the present study patients with EBC without distant metastasis were enrolled, which could account for the different results. CEA and CA15-3 are associated with BC prognosis and have been therefore widely used in clinical surveillance of BC (32,33). However, their use in screening and diagnosis of EBC has not been yet verified (34).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and prognostic significance of SLC50A1 expression in patients with primary early breast cancer

et al. 2022

View full text Add to dashboard Cite

There is a lack of validated biomarkers for the diagnosis of early breast cancer (EBC). The current study aimed to determine the diagnostic and prognostic value of solute carrier family 50 member 1 (SLC50A1) in patients with EBC. Therefore, 123 patients with EBC, 30 patients with benign breast disease (BBD) and 26 healthy controls (HCs) were recruited. The serum levels of SLC50A1 in paired sera of 40 postoperative patients were assessed by ELISA. Immunohistochemical staining for SLC50A1 was performed in surgical tissue derived from 83 patients with EBC and 30 patients with BBD. mRNA expression of SLC50A1 and its diagnostic and prognostic value in patients with EBC was evaluated using an RNA-sequencing database. The results showed that serum levels of SLC50A1 in patients with EBC were significantly higher compared with those in patients with BBD and HCs (both P<0.001). Additionally, receiver operating characteristic curve analysis revealed that the serum levels of SLC50A1 distinguished patients with EBC from patients with BBD and HCs with a sensitivity of 76.42% and specificity of 76.79% [area under the curve (AUC)=0.783; P<0.001]. The diagnostic value of SLC50A1 was significantly greater than that of carcinoembryonic (P<0.005) and carbohydrate antigen 15-3 (P<0.029). Furthermore, the number of SLC50A1 positive cells significantly increased in tissue of patients with EBC compared with patients with BBD (P<0.001). A positive association between serum levels of SLC50A1 and its expression in tissue samples was observed in patients with EBC (ρ=0.700; P<0.001). Additionally, bioinformatics analysis verified the diagnostic value of SLC50A1, with an AUC of 0.983 (P<0.001). Multivariate analysis demonstrated that SLC50A1 was an independent prognostic factor in patients with EBC with a hazard ratio of 1.917 (P=0.013). These findings indicated that SLC50A1 may be a potential diagnostic biomarker for primary EBC and that SLC50A1 upregulation may be associated with unfavorable prognosis in patients with EBC.

show abstract

“…Serum CA 125 concentration correlates with TNM stage, histological type, and survival rate in patients with lung cancer [ 14 ]. CYFRA21-1, a cytokeratin 19 soluble fragment, is a newly discovered monoclonal antibody with comparative diagnostic value in detecting nonsmall cell lung cancer (NSCLC), particularly in patients with squamous cell carcinoma (SCC) [ 15 ]. Serum CYFRA21-1 shows promise as a biomarker for differentiating small cell lung cancer (SCLC) from NSCLC [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Determination of Tumor Marker Screening for Lung Cancer Using ROC Curves

Dou,

Lu,

et al. 2024

Disease Markers

View full text Add to dashboard Cite

Introduction. Lung cancer ranks first among malignant tumors worldwide and is a leading cause of cancer-related mortality in both men and women. Combining tumor marker testing is a strategy to screen individuals at high risk of pulmonary cancer and minimize pulmonary cancer mortality. Therefore, tumor marker screening is crucial. In this study, we analyzed combinations of tumor markers for lung cancer screening using receiver operating characteristic (ROC) curve analysis. Methods. A retrospective descriptive study was conducted on patients diagnosed with lung cancer, as well as healthy and benign lung diseases, using data from the China Huludao Central Hospital database between January 2016 and July 2022. The t-test and ROC curve were utilized to assess the effectiveness of individual tumor marker and the combination of multiple tumor markers. Tumor markers are molecular products metabolized and secreted by tumor tissues, characterized by cells or body fluids. They serve as indicators of tumor stage and grading, monitor treatment response, and predict recurrence. Results. In this study, 267 healthy participants, 385 patients with benign lesions, and 296 patients with lung cancer underwent tumor marker screening. The sensitivity of five tumor markers—CEA, CYFRA21-1, NSE, pro-GRP, and CA125—was found to be <55%. This study revealed that a single tumor marker had limited value in lung cancer screening. However, combining two or more markers yielded varying area under the curves (AUC), with no significant impact on screening accuracy. The combination of CEA + CA125 demonstrated the highest accuracy for lung cancer screening in healthy participants. At a cutoff of 0.447 for CEA + CA125, the combination showed a sensitivity of 0.676 and specificity of 0.846 for lung cancer screening. Conversely, for patients with benign lung lesions, the optimal combination was CEA + NSE, with a cutoff of 0.393, yielding a sensitivity of 0.645 and specificity of 0.766 for lung cancer screening. Conclusion. The five tumor markers—CEA, CA125, CY211, NSE, GRP—show promising results in screening healthy individuals and patients with lung cancer. However, only CEA, NSE, and GRP effectively differentiate patients with benign lung lesions from those with lung cancer. A single tumor marker has limited utility in detecting and screening for lung cancer and should be combined with other tumor markers. CEA + CA125 emerges as a superior tumor marker for distinguishing healthy individuals from those with lung cancer, whereas the CEA + NSE combination is more effective in identifying tumor markers in patients with benign lung lesions and lung cancer.

show abstract

Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer

Cited by 14 publications

References 34 publications

Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions

Carcinoembryonic antigen in the diagnosis, treatment, and follow-up of focal liver lesions

Diagnostic and prognostic significance of SLC50A1 expression in patients with primary early breast cancer

Determination of Tumor Marker Screening for Lung Cancer Using ROC Curves

Contact Info

Product

Resources

About